<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00083174</url>
  </required_header>
  <id_info>
    <org_study_id>MAP3</org_study_id>
    <secondary_id>CAN-NCIC-MAP3</secondary_id>
    <secondary_id>PFIZER-EXEAPO-0028-150</secondary_id>
    <secondary_id>ExCel</secondary_id>
    <secondary_id>CDR0000363802</secondary_id>
    <nct_id>NCT00083174</nct_id>
    <nct_alias>NCT00304486</nct_alias>
  </id_info>
  <brief_title>Exemestane in Preventing Cancer in Postmenopausal Women at Increased Risk of Developing Breast Cancer</brief_title>
  <official_title>A Phase III Randomized Study of Exemestane Versus Placebo in Postmenopausal Women at Increased Risk of Developing Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NCIC Clinical Trials Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Grupo Espanol de Investigacion del Cancer de Mama</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>UNICANCER</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Canadian Cancer Trials Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: The MAP.3 study was designed to test whether hormone therapy using exemestane may
      prevent breast cancer by blocking the production of estrogen.

      PURPOSE: The study protocol was amended in May 2011 and the current purpose of the study is
      to allow all study participants the opportunity to complete 5 years of exemestane.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

      Primary

      Previously: To determine if exemestane reduces the incidence of invasive breast cancer
      compared with placebo.

      Currently: To determine the frequency of serious adverse events for post-menopausal women at
      high-risk of developing breast cancer who choose to receive 5 years of exemestane as
      preventative therapy.

      Secondary

      Previously: (same as is currently listed in PDQ) Currently: To address the Trial Committee
      and Sponsor's commitment to allow women who are randomized to the MAP.3 trial to receive 5
      years of exemestane therapy.

      OUTLINE: This study was a randomized, double-blind, placebo-controlled, multicentre study.
      Protocol-specified analyses were performed in April 2011. The results of these analyses are
      posted in the Results section. Following the amendment of May 2011, the study is now
      open-label and all eligible patients are receiving exemestane from participating sites for a
      total of 5 years. After exemestane is stopped, there is no further follow-up.

      PROJECTED ACCRUAL:There were 4560 women from the United States, Canada, Spain and France who
      took part in this study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 11, 2004</start_date>
  <completion_date type="Actual">January 22, 2018</completion_date>
  <primary_completion_date type="Actual">March 25, 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Women With Serious Adverse Events</measure>
    <time_frame>5 years open-label extension period</time_frame>
    <description>Percentage of serious adverse events for women who choose to receive 5 years of exemestane as preventative therapy.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Invasive Breast Cancer Incidence (Breast Cancer-Free Survival)</measure>
    <time_frame>Over randomization period of study (median follow-up 35 months)</time_frame>
    <description>Invasive breast cancer incidence was estimated from the breast cancer-free survival (BCFS) which was calculated for all women from the day of the randomization to the earliest date of diagnosis for invasive breast cancer. Women who died from other causes were censored at the time of death. If a woman did not develop an invasive breast cancer, or died, BCFS was censored on the date of the last day the woman was known alive (LKA), which was the latest of the date of assessment. Women who had breast cancer before study entry were also censored at the time of randomization.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Total Incidence of Invasive and Non-invasive (DCIS) Breast Cancer</measure>
    <time_frame>Over randomization period of study (median follow-up 35 months)</time_frame>
    <description>It was estimated from the Total Breast Cancer-Free Survival (TBCFS), which was calculated for women who developed invasive or non-invasive (DCIS) breast cancer as the time from the date of randomization to the earliest date of diagnosis for invasive or non-invasive (DCIS) breast cancer. Women who died from other causes were censored at the time of death. Women who had breast cancer before entry were censored at the time of randomization. If a woman did not develop an invasive or non-invasive (DCIS) breast cancer, or died, TBCFS will be censored on the date of last known alive.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Lobular Carcinoma in Situ, Atypical Ductal Hyperplasia and Atypical Lobular Hyperplasia Events</measure>
    <time_frame>Over randomization period of study (median follow-up 35 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Clinical Breast Biopsies</measure>
    <time_frame>Over randomization period of study (median follow-up 35 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of All Clinical Fractures</measure>
    <time_frame>During protocol treatment over randomization period of study (up to 5 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Clinically Relevant Cardiac Events</measure>
    <time_frame>During protocol treatment in randomization period (up to 5 years)</time_frame>
    <description>Events including myocardial infarctions and angina requiring percutaneous transluminal coronary angioplasty or coronary artery bypass graft, fatal and nonfatal strokes and all vascular deaths</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidences of Other Malignancies</measure>
    <time_frame>Over randomization period of study (median follow-up 35 months)</time_frame>
    <description>Other malignancies includes any other malignancy which is not in breast.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">4560</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Exemestane</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>one 25 mg tablet daily in am</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>exemestane</intervention_name>
    <description>one 25 mg tablet daily in am</description>
    <arm_group_label>Exemestane</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  At increased risk of developing breast cancer, due to at least one of the following
             risk factors:

               -  Gail score ≥ 1.66

               -  Age ≥ 60 years

               -  Prior atypical ductal hyperplasia, lobular hyperplasia, or lobular carcinoma in
                  situ on breast biopsy

               -  Prior ductal carcinoma in situ (DCIS) treated with total mastectomy with or
                  without tamoxifen (tamoxifen must have been completed ≥ 3 months prior to
                  randomization)

          -  No prior DCIS treated with lumpectomy with or without radiation

          -  No prior invasive breast cancer

          -  Not BRCA1 or BRCA2 carriers

        PATIENT CHARACTERISTICS:

        Previous:

          -  35 and over

          -  Female

          -  Postmenopausal, defined as one of the following:

               -  over 50 years of age with no spontaneous menses for at least 12 months before
                  study entry

               -  50 years of age or under with no menses (spontaneous or secondary to
                  hysterectomy) for at least 12 months before study entry AND with
                  follicle-stimulating hormone level within postmenopausal range

               -  Underwent prior bilateral oophorectomy

          -  No other malignancies within the past 5 years except adequately treated nonmelanoma
             skin cancer, curatively treated carcinoma in situ of the cervix, or other curatively
             treated solid tumors with no evidence of disease for ≥ 5 years

          -  No uncontrolled hypothyroidism or hyperthyroidism

          -  No major medical or psychiatric illness (including substance and alcohol abuse within
             the past 2 years) that would preclude study participation or compliance

          -  Must be accessible for treatment and follow-up

          -  Willing to complete quality of life questionnaires in either English or French

        Current: MAP.3 participants who were randomized to the exemestane arm, are currently
        receiving exemestane as part of the MAP.3 study and who have not completed 5 years of
        exemestane.

        OR MAP.3 study participants who were randomized to the placebo arm and who have either
        completed 5 years of study drug or who are still receiving placebo. Note: this applies only
        to centres that choose to allow placebo &quot;cross-over&quot;.

        PRIOR CONCURRENT THERAPY:

        Previous:

          -  More than 3 months since prior and no concurrent hormone replacement therapies

          -  More than 3 months since systemic estrogenic, androgenic, or progestational agents

          -  More than 3 months since prior and no concurrent hormonal therapies, including, but
             not limited to the following:

               -  Luteinizing-hormone releasing-hormone analogs (e.g., goserelin or leuprolide)

               -  Progestogens (e.g., megestrol)

               -  Prolactin inhibitors (e.g., bromocriptine)

               -  Antiandrogens (e.g., cyproterone acetate)

               -  Selective estrogen-receptor modulators (e.g., tamoxifen, toremifene, or
                  raloxifene)

          -  No investigational drug within 30 days or 5 half lives prior to randomization

          -  No concurrent endocrine therapy

          -  No concurrent estrogens, androgens, or progesterones

          -  Concurrent low dose (≤ 100 mg/day) prophylactic aspirin allowed

          -  Concurrent bisphosphonates for prevention or treatment of osteoporosis allowed

          -  No other concurrent medications that may have an effect on study endpoints

        Current: There are no prior concurrent therapy restrictions for the amended MAP.3 study.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paul E. Goss, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Jefferson Clinic, P.C.</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UAB Comprehensive Cancer Center-LNB 301</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294-0111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Providence Alaska Medical Center</name>
      <address>
        <city>Anchorage</city>
        <state>Alaska</state>
        <zip>99508</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California, San Diego</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California at Davis</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Los Angeles Biomedical Research Institute</name>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <zip>90502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Connecticut Health Center</name>
      <address>
        <city>Farmington</city>
        <state>Connecticut</state>
        <zip>06032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Whittingham Cancer Center at Norwalk Hospital</name>
      <address>
        <city>Norwalk</city>
        <state>Connecticut</state>
        <zip>06856</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The George Washington University</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Jacksonville</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Miami School of Medicine</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Georgia Cancer Specialists</name>
      <address>
        <city>Tucker</city>
        <state>Georgia</state>
        <zip>30084</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>John H. Stroger, Jr Hospital of Cook County</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mercy Hospital and Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60616</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The University of Chicago Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637-1470</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Loyola University Medical Centre</name>
      <address>
        <city>Maywood</city>
        <state>Illinois</state>
        <zip>60153</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Trinity Medical Center</name>
      <address>
        <city>Moline</city>
        <state>Illinois</state>
        <zip>61265</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mid-Illinois Hematology and Oncology Associates, Ltd.</name>
      <address>
        <city>Normal</city>
        <state>Illinois</state>
        <zip>61761</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Carle Cancer Centre</name>
      <address>
        <city>Urbana</city>
        <state>Illinois</state>
        <zip>61801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana University Medical Center</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Kansas Medical Center</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160-7820</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maine Center for Cancer Medicine and Blood Disorders</name>
      <address>
        <city>Scarborough</city>
        <state>Maine</state>
        <zip>04074-9308</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Suburban Hospital Cancer Program</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MedStar Health Research Institute</name>
      <address>
        <city>Hyattsville</city>
        <state>Maryland</state>
        <zip>20782</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hutzel Women's Health Specialists</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>William Beaumont Hospital</name>
      <address>
        <city>Royal Oak</city>
        <state>Michigan</state>
        <zip>48073</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Rochester</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Medicine and Dentistry of New Jersey</name>
      <address>
        <city>Newark</city>
        <state>New Jersey</state>
        <zip>07107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Montefiore Medical Center</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10461</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kinston Medical Specialists</name>
      <address>
        <city>Kinston</city>
        <state>North Carolina</state>
        <zip>28501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Cincinnati, Barrett Cancer Centre</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Oklahoma</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Abramson Cancer Center of the</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104-4283</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Memorial Hospital of Rhode Island</name>
      <address>
        <city>Pawtucket</city>
        <state>Rhode Island</state>
        <zip>02860</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fletcher Allen Health Care</name>
      <address>
        <city>Burlington</city>
        <state>Vermont</state>
        <zip>05401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fred Hutchinson Cancer Research Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109-1024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ. of Wisconsin Center for Women's Health and</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53715</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical College of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BCCA - Cancer Centre for the Southern Interior</name>
      <address>
        <city>Kelowna</city>
        <state>British Columbia</state>
        <zip>V1Y 5L3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BCCA - Vancouver Cancer Centre</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 4E6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CancerCare Manitoba</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R3E 0V9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Atlantic Health Sciences Corporation</name>
      <address>
        <city>Saint John</city>
        <state>New Brunswick</state>
        <zip>E2L 4L2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Juravinski Cancer Centre at Hamilton Health Sciences</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8V 5C2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Centre of Southeastern Ontario at Kingston</name>
      <address>
        <city>Kingston</city>
        <state>Ontario</state>
        <zip>K7L 5P9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>London Regional Cancer Program</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 4L6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ottawa Health Research Institute - General Division</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1H 8L6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Meadowlands Family Health Centre</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K2C 3R2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Algoma District Cancer Program</name>
      <address>
        <city>Sault Ste. Marie</city>
        <state>Ontario</state>
        <zip>P6B 0A8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northeast Cancer Center Health Sciences</name>
      <address>
        <city>Sudbury</city>
        <state>Ontario</state>
        <zip>P3E 5J1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Toronto East General Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4C 3E7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Odette Cancer Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4N 3M5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mount Sinai Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 1X5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ. Health Network-Princess Margaret Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Women's College Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5S 1B2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Maisonneuve-Rosemont</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H1T 2M4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHUM - Hopital Notre-Dame</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2L 4M1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHUM - Pavillon Saint-Luc</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3X 3J4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHA-Hopital Du St-Sacrement</name>
      <address>
        <city>Quebec City</city>
        <state>Quebec</state>
        <zip>G1S 4L8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CRLCC - Paul Papin</name>
      <address>
        <city>Angers</city>
        <zip>49933</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU-Hopital A. Morvan</name>
      <address>
        <city>Brest</city>
        <zip>29608</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Francois Baclesse</name>
      <address>
        <city>Caen</city>
        <zip>14076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Limoges - Hopital Mere Enfant</name>
      <address>
        <city>Limoges</city>
        <zip>87042</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU - Hopital Arnaud de Villeneuve</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Rene Gauducheau</name>
      <address>
        <city>Nantes</city>
        <zip>44805</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique Hartmann</name>
      <address>
        <city>Neuilly-sur-Seine</city>
        <zip>92200</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AP-HP Hopital Tenon</name>
      <address>
        <city>Paris</city>
        <zip>75970</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Jean Godinot</name>
      <address>
        <city>Reims</city>
        <zip>51056</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Henri Becquerel</name>
      <address>
        <city>Rouen</city>
        <zip>76038</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Rene Huguenin</name>
      <address>
        <city>Saint Cloud</city>
        <zip>92210</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Alexis Vautrin</name>
      <address>
        <city>Vandoeuvre les Nancy</city>
        <zip>54500</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Gustave-Roussy</name>
      <address>
        <city>Villejuif</city>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Orocovis Medical Center</name>
      <address>
        <city>Orocovis</city>
        <zip>00720</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altamira Family Research Center</name>
      <address>
        <city>San Juan</city>
        <zip>00920</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>France</country>
    <country>Puerto Rico</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Spain</country>
  </removed_countries>
  <link>
    <url>http://www.excelstudy.com/</url>
    <description>Web site for additional information</description>
  </link>
  <reference>
    <citation>Richardson H, Johnston D, Pater J, Goss P. The National Cancer Institute of Canada Clinical Trials Group MAP.3 trial: an international breast cancer prevention trial. Curr Oncol. 2007 Jun;14(3):89-96.</citation>
    <PMID>17593981</PMID>
  </reference>
  <results_reference>
    <citation>Goss PE, Richardson H, Chlebowski R, Johnston D, Sarto GE, Maunsell E, Ingle JN, Alés-Martinez JE. National Cancer Institute of Canada Clinical Trials Group MAP.3 Trial: evaluation of exemestane to prevent breast cancer in postmenopausal women. Clin Breast Cancer. 2007 Dec;7(11):895-900. doi: 10.3816/CBC.2007.n.057.</citation>
    <PMID>18269782</PMID>
  </results_reference>
  <results_reference>
    <citation>Moy B, Richardson H, Johnston D, et al.: NCIC CTG MAP.3: enrollment and study drug adherence of ethnic minority women in a breast cancer prevention trial. [Abstract] Breast Cancer Res Treat 106 (1): A-3048, S141-2, 2007.</citation>
  </results_reference>
  <results_reference>
    <citation>Richardson H, Johnston D, Goss PE, et al.: Participant characteristics on an international NCIC CTG breast cancer prevention trial. [Abstract] J Clin Oncol 25 (Suppl 18): A-1531, 2007.</citation>
  </results_reference>
  <results_reference>
    <citation>Goss PE, Ingle JN, Alés-Martinez J, Cheung A, Chlebowski RT, Wactawski-Wende J, McTiernan A, Robbins J, Johnson K, Martin L, Winquist E, Sarto G, Garber JE, Fabian CJ, Pujol P, Maunsell E, Farmer P, Gelmon KA, Tu D, Richardson H. Exemestane for primary prevention of breast cancer in postmenopausal women: NCIC CTG MAP.3 - A randomized placebo-controlled clinical trial. J Clin Oncol 29[suppl; abstr LBA504], 2011.</citation>
  </results_reference>
  <results_reference>
    <citation>Goss PE, Ingle JN, Alés-Martínez JE, Cheung AM, Chlebowski RT, Wactawski-Wende J, McTiernan A, Robbins J, Johnson KC, Martin LW, Winquist E, Sarto GE, Garber JE, Fabian CJ, Pujol P, Maunsell E, Farmer P, Gelmon KA, Tu D, Richardson H; NCIC CTG MAP.3 Study Investigators. Exemestane for breast-cancer prevention in postmenopausal women. N Engl J Med. 2011 Jun 23;364(25):2381-91. doi: 10.1056/NEJMoa1103507. Epub 2011 Jun 4. Erratum in: N Engl J Med. 2011 Oct 6;365(14):1361.</citation>
    <PMID>21639806</PMID>
  </results_reference>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 14, 2004</study_first_submitted>
  <study_first_submitted_qc>May 14, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 17, 2004</study_first_posted>
  <results_first_submitted>November 7, 2012</results_first_submitted>
  <results_first_submitted_qc>May 16, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 20, 2013</results_first_posted>
  <last_update_submitted>March 27, 2018</last_update_submitted>
  <last_update_submitted_qc>March 27, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 25, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Exemestane</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Between February 11, 2004, and March 23, 2010, 4560 women were recruited in medical clinics.</recruitment_details>
      <pre_assignment_details>Eligibility of women was first checked before the randomization to the trial.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Randomization Period: Exemestane</title>
          <description>one 25 mg tablet daily in am</description>
        </group>
        <group group_id="P2">
          <title>Randomization Period: Placebo</title>
          <description>one tablet daily in am</description>
        </group>
        <group group_id="P3">
          <title>Open-label Extension: Exemestane</title>
          <description>one 25 mg tablet daily in am</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Randomization Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2285"/>
                <participants group_id="P2" count="2275"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2285">All women randomized were included in the analysis based on intent-to-treat principle.</participants>
                <participants group_id="P2" count="2275">All women randomized were included in the analysis based on intent-to-treat principle.</participants>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Open-label Extension</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2831"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2831"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Randomization Period: Exemestane</title>
          <description>one 25 mg tablet daily in am</description>
        </group>
        <group group_id="B2">
          <title>Randomization Period: Placebo</title>
          <description>one tablet daily in am</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="2285"/>
            <count group_id="B2" value="2275"/>
            <count group_id="B3" value="4560"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1458"/>
                    <measurement group_id="B2" value="1481"/>
                    <measurement group_id="B3" value="2939"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="827"/>
                    <measurement group_id="B2" value="794"/>
                    <measurement group_id="B3" value="1621"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63.1" spread="7.2"/>
                    <measurement group_id="B2" value="63.1" spread="7.0"/>
                    <measurement group_id="B3" value="63.1" spread="7.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2285"/>
                    <measurement group_id="B2" value="2275"/>
                    <measurement group_id="B3" value="4560"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1416"/>
                    <measurement group_id="B2" value="1408"/>
                    <measurement group_id="B3" value="2824"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>France</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="643"/>
                    <measurement group_id="B2" value="642"/>
                    <measurement group_id="B3" value="1285"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Spain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="217"/>
                    <measurement group_id="B2" value="215"/>
                    <measurement group_id="B3" value="432"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Women With Serious Adverse Events</title>
        <description>Percentage of serious adverse events for women who choose to receive 5 years of exemestane as preventative therapy.</description>
        <time_frame>5 years open-label extension period</time_frame>
        <population>Postmenopausal women who were randomized to exemestane in original MAP.3 study and chose to continue to receive exemestane for up to 5 years and those randomized to placebo and decided to start 5 years of exemestane.</population>
        <group_list>
          <group group_id="O1">
            <title>Open-label Extension: Exemestane</title>
            <description>one 25 mg tablet daily in am
exemestane: one 25 mg tablet daily in am</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Women With Serious Adverse Events</title>
          <description>Percentage of serious adverse events for women who choose to receive 5 years of exemestane as preventative therapy.</description>
          <population>Postmenopausal women who were randomized to exemestane in original MAP.3 study and chose to continue to receive exemestane for up to 5 years and those randomized to placebo and decided to start 5 years of exemestane.</population>
          <units>percentage of women</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2831"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Invasive Breast Cancer Incidence (Breast Cancer-Free Survival)</title>
        <description>Invasive breast cancer incidence was estimated from the breast cancer-free survival (BCFS) which was calculated for all women from the day of the randomization to the earliest date of diagnosis for invasive breast cancer. Women who died from other causes were censored at the time of death. If a woman did not develop an invasive breast cancer, or died, BCFS was censored on the date of the last day the woman was known alive (LKA), which was the latest of the date of assessment. Women who had breast cancer before study entry were also censored at the time of randomization.</description>
        <time_frame>Over randomization period of study (median follow-up 35 months)</time_frame>
        <population>intention to treat (ITT)</population>
        <group_list>
          <group group_id="O1">
            <title>Randomization Period: Exemestane</title>
            <description>25 mg of exemestane tablet daily</description>
          </group>
          <group group_id="O2">
            <title>Randomization Period: Placebo</title>
            <description>Placebo tablet daily</description>
          </group>
        </group_list>
        <measure>
          <title>Invasive Breast Cancer Incidence (Breast Cancer-Free Survival)</title>
          <description>Invasive breast cancer incidence was estimated from the breast cancer-free survival (BCFS) which was calculated for all women from the day of the randomization to the earliest date of diagnosis for invasive breast cancer. Women who died from other causes were censored at the time of death. If a woman did not develop an invasive breast cancer, or died, BCFS was censored on the date of the last day the woman was known alive (LKA), which was the latest of the date of assessment. Women who had breast cancer before study entry were also censored at the time of randomization.</description>
          <population>intention to treat (ITT)</population>
          <units>percentage of cases/follow-up person-yr</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2285"/>
                <count group_id="O2" value="2275"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.19" lower_limit="0.08" upper_limit="0.30"/>
                    <measurement group_id="O2" value="0.55" lower_limit="0.36" upper_limit="0.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was no difference between two groups. The sample size estimate was based on an assumption of annual invasive breast cancer rate of 0.60% in the placebo group and 0.21% in exemestane group, a relative reduction of 65% with exemestane. To detect this with a two-sided 5% level and 90% power, a total of 38 cases of invasive breast cancer were required, projected to occur when 4560 women were randomly assigned in a 3-year period and then followed for an additional 1.2 years.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.002</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.35</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.18</ci_lower_limit>
            <ci_upper_limit>0.70</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Incidence of Invasive and Non-invasive (DCIS) Breast Cancer</title>
        <description>It was estimated from the Total Breast Cancer-Free Survival (TBCFS), which was calculated for women who developed invasive or non-invasive (DCIS) breast cancer as the time from the date of randomization to the earliest date of diagnosis for invasive or non-invasive (DCIS) breast cancer. Women who died from other causes were censored at the time of death. Women who had breast cancer before entry were censored at the time of randomization. If a woman did not develop an invasive or non-invasive (DCIS) breast cancer, or died, TBCFS will be censored on the date of last known alive.</description>
        <time_frame>Over randomization period of study (median follow-up 35 months)</time_frame>
        <population>Intent-to-treat (ITT)</population>
        <group_list>
          <group group_id="O1">
            <title>Randomization Period: Exemestane</title>
            <description>one 25 mg tablet daily in am</description>
          </group>
          <group group_id="O2">
            <title>Randomization Period: Placebo</title>
            <description>one tablet daily in am</description>
          </group>
        </group_list>
        <measure>
          <title>Total Incidence of Invasive and Non-invasive (DCIS) Breast Cancer</title>
          <description>It was estimated from the Total Breast Cancer-Free Survival (TBCFS), which was calculated for women who developed invasive or non-invasive (DCIS) breast cancer as the time from the date of randomization to the earliest date of diagnosis for invasive or non-invasive (DCIS) breast cancer. Women who died from other causes were censored at the time of death. Women who had breast cancer before entry were censored at the time of randomization. If a woman did not develop an invasive or non-invasive (DCIS) breast cancer, or died, TBCFS will be censored on the date of last known alive.</description>
          <population>Intent-to-treat (ITT)</population>
          <units>percentage of cases/follow-up person-yr</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2285"/>
                <count group_id="O2" value="2275"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.35" lower_limit="0.20" upper_limit="0.50"/>
                    <measurement group_id="O2" value="0.77" lower_limit="0.54" upper_limit="0.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.004</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.47</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.27</ci_lower_limit>
            <ci_upper_limit>0.79</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Lobular Carcinoma in Situ, Atypical Ductal Hyperplasia and Atypical Lobular Hyperplasia Events</title>
        <time_frame>Over randomization period of study (median follow-up 35 months)</time_frame>
        <population>Intent-to-treat (ITT)</population>
        <group_list>
          <group group_id="O1">
            <title>Randomization Period: Exemestane</title>
            <description>one 25 mg tablet daily in am</description>
          </group>
          <group group_id="O2">
            <title>Randomization Period: Placebo</title>
            <description>one tablet daily in am</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Lobular Carcinoma in Situ, Atypical Ductal Hyperplasia and Atypical Lobular Hyperplasia Events</title>
          <population>Intent-to-treat (ITT)</population>
          <units>percentage of cases/follow-up person-yr</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2285"/>
                <count group_id="O2" value="2275"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.07" lower_limit="0.00" upper_limit="0.15"/>
                    <measurement group_id="O2" value="0.20" lower_limit="0.08" upper_limit="0.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.07</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.36</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.11</ci_lower_limit>
            <ci_upper_limit>1.12</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Clinical Breast Biopsies</title>
        <time_frame>Over randomization period of study (median follow-up 35 months)</time_frame>
        <population>Women who had at least one clinical breast biopsy</population>
        <group_list>
          <group group_id="O1">
            <title>Randomization Period: Exemestane</title>
            <description>one 25 mg tablet daily in am</description>
          </group>
          <group group_id="O2">
            <title>Randomization Period: Placebo</title>
            <description>one tablet daily in am</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Clinical Breast Biopsies</title>
          <population>Women who had at least one clinical breast biopsy</population>
          <units>number of clinical breast biopsies</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="81"/>
                <count group_id="O2" value="118"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" lower_limit="1" upper_limit="3"/>
                    <measurement group_id="O2" value="1" lower_limit="1" upper_limit="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of All Clinical Fractures</title>
        <time_frame>During protocol treatment over randomization period of study (up to 5 years)</time_frame>
        <population>Women who have received treatment</population>
        <group_list>
          <group group_id="O1">
            <title>Randomization Period: Exemestane</title>
            <description>one 25 mg tablet daily in am</description>
          </group>
          <group group_id="O2">
            <title>Randomization Period: Placebo</title>
            <description>one tablet daily in am</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of All Clinical Fractures</title>
          <population>Women who have received treatment</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2240"/>
                <count group_id="O2" value="2248"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="149"/>
                    <measurement group_id="O2" value="143"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Clinically Relevant Cardiac Events</title>
        <description>Events including myocardial infarctions and angina requiring percutaneous transluminal coronary angioplasty or coronary artery bypass graft, fatal and nonfatal strokes and all vascular deaths</description>
        <time_frame>During protocol treatment in randomization period (up to 5 years)</time_frame>
        <population>Women who received treatment during randomization period</population>
        <group_list>
          <group group_id="O1">
            <title>Randomization Period: Exemestane</title>
            <description>one 25 mg tablet daily in am</description>
          </group>
          <group group_id="O2">
            <title>Randomization Period: Placebo</title>
            <description>one tablet daily in am</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Clinically Relevant Cardiac Events</title>
          <description>Events including myocardial infarctions and angina requiring percutaneous transluminal coronary angioplasty or coronary artery bypass graft, fatal and nonfatal strokes and all vascular deaths</description>
          <population>Women who received treatment during randomization period</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2240"/>
                <count group_id="O2" value="2248"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="106"/>
                    <measurement group_id="O2" value="111"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidences of Other Malignancies</title>
        <description>Other malignancies includes any other malignancy which is not in breast.</description>
        <time_frame>Over randomization period of study (median follow-up 35 months)</time_frame>
        <population>Women who have received treatment</population>
        <group_list>
          <group group_id="O1">
            <title>Randomization Period: Exemestane</title>
            <description>one 25 mg tablet daily in am</description>
          </group>
          <group group_id="O2">
            <title>Randomization Period: Placebo</title>
            <description>one tablet daily in am</description>
          </group>
        </group_list>
        <measure>
          <title>Incidences of Other Malignancies</title>
          <description>Other malignancies includes any other malignancy which is not in breast.</description>
          <population>Women who have received treatment</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2240"/>
                <count group_id="O2" value="2248"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50"/>
                    <measurement group_id="O2" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Participants were followed for a median of 35 months over randomization period of study for randomization period and 5 years for open-label extension period</time_frame>
      <desc>During 5 year open-label extension, only SAE was monitored.</desc>
      <group_list>
        <group group_id="E1">
          <title>Randomization Period: Exemestane</title>
          <description>one 25 mg tablet daily in am</description>
        </group>
        <group group_id="E2">
          <title>Randomization Period: Placebo</title>
          <description>one tablet daily in am</description>
        </group>
        <group group_id="E3">
          <title>Open-label Extension: Exemestane</title>
          <description>one 25 mg tablet daily in am</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE, version 3.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="39" subjects_at_risk="2240"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="2248"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2831"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Supraven.arrhyth. Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2240"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2248"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2831"/>
              </event>
              <event>
                <sub_title>Cardiac ischemia/infarction</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2240"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2248"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2831"/>
              </event>
              <event>
                <sub_title>Valvular heart disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2240"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2248"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2831"/>
              </event>
              <event>
                <sub_title>Cardiac General - Other</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2240"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2248"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2831"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Endocrine - Other</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2240"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2248"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2831"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Ocular - Other</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2240"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2248"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2831"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2240"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2248"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2831"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2240"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2248"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2831"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2240"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2248"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2831"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2240"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2248"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2831"/>
              </event>
              <event>
                <sub_title>Incontinence, anal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2240"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2248"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2831"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2240"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2248"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2831"/>
              </event>
              <event>
                <sub_title>Obstruction, GI Stomach</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2240"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2248"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2831"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2240"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2248"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2831"/>
              </event>
              <event>
                <sub_title>GI - Other</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2240"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2248"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2831"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Sudden death</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2240"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2248"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2831"/>
              </event>
              <event>
                <sub_title>Pain Abdomen NOS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2240"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2248"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2831"/>
              </event>
              <event>
                <sub_title>Pain Back</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2240"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2248"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2831"/>
              </event>
              <event>
                <sub_title>Pain Joint</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2240"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2248"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2831"/>
              </event>
              <event>
                <sub_title>Syndromes - Other</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2240"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2248"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2831"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2240"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2248"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2831"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2240"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2248"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2831"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergic reaction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2240"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2248"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2831"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infec.w.norm.ANC Upper airway NOS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2240"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2248"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2831"/>
              </event>
              <event>
                <sub_title>Infection (doc.clin.) Lung</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2240"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2248"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2831"/>
              </event>
              <event>
                <sub_title>Infection - Other</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2240"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2248"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2831"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>ALT</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2240"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2248"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2831"/>
              </event>
              <event>
                <sub_title>AST</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2240"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2248"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2831"/>
              </event>
              <event>
                <sub_title>Alkaline phosphatase</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2240"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2248"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2831"/>
              </event>
              <event>
                <sub_title>Creatinine</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2240"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2248"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2831"/>
              </event>
              <event>
                <sub_title>GGT</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2240"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2248"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2831"/>
              </event>
              <event>
                <sub_title>Hypercalcemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2240"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2248"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2831"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2240"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2248"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2831"/>
              </event>
              <event>
                <sub_title>Fracture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2240"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2248"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2831"/>
              </event>
              <event>
                <sub_title>Musculoskeletal - Other</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2240"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2248"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2831"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Secondary Malignancy</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2240"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2248"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2831"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>CNS ischemia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="2240"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="2248"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2831"/>
              </event>
              <event>
                <sub_title>Memory impairment</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2240"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2248"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2831"/>
              </event>
              <event>
                <sub_title>Neuropathy-sensory</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2240"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2248"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2831"/>
              </event>
              <event>
                <sub_title>Neurology - Other</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2240"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2248"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2831"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2240"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2248"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2831"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2240"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2248"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2831"/>
              </event>
              <event>
                <sub_title>Pulmonary - Other</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2240"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2248"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2831"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2240"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2248"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2831"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Thrombosis/thrombus/embolism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2240"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2248"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2831"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE, version 3.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1963" subjects_at_risk="2240"/>
                <counts group_id="E2" subjects_affected="1901" subjects_at_risk="2248"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>hypertension</sub_title>
                <counts group_id="E1" subjects_affected="341" subjects_at_risk="2240"/>
                <counts group_id="E2" subjects_affected="354" subjects_at_risk="2248"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>hot flashes</sub_title>
                <counts group_id="E1" subjects_affected="900" subjects_at_risk="2240"/>
                <counts group_id="E2" subjects_affected="718" subjects_at_risk="2248"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>fatigue</sub_title>
                <counts group_id="E1" subjects_affected="525" subjects_at_risk="2240"/>
                <counts group_id="E2" subjects_affected="465" subjects_at_risk="2248"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>sweating</sub_title>
                <counts group_id="E1" subjects_affected="486" subjects_at_risk="2240"/>
                <counts group_id="E2" subjects_affected="433" subjects_at_risk="2248"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>insomnia</sub_title>
                <counts group_id="E1" subjects_affected="230" subjects_at_risk="2240"/>
                <counts group_id="E2" subjects_affected="189" subjects_at_risk="2248"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="118" subjects_at_risk="2240"/>
                <counts group_id="E2" subjects_affected="75" subjects_at_risk="2248"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>heartburn</sub_title>
                <counts group_id="E1" subjects_affected="332" subjects_at_risk="2240"/>
                <counts group_id="E2" subjects_affected="289" subjects_at_risk="2248"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="155" subjects_at_risk="2240"/>
                <counts group_id="E2" subjects_affected="122" subjects_at_risk="2248"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pain Back</sub_title>
                <counts group_id="E1" subjects_affected="306" subjects_at_risk="2240"/>
                <counts group_id="E2" subjects_affected="222" subjects_at_risk="2248"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>pain extremity</sub_title>
                <counts group_id="E1" subjects_affected="153" subjects_at_risk="2240"/>
                <counts group_id="E2" subjects_affected="122" subjects_at_risk="2248"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Pain Joint</sub_title>
                <counts group_id="E1" subjects_affected="665" subjects_at_risk="2240"/>
                <counts group_id="E2" subjects_affected="606" subjects_at_risk="2248"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>pain muscle</sub_title>
                <counts group_id="E1" subjects_affected="147" subjects_at_risk="2240"/>
                <counts group_id="E2" subjects_affected="192" subjects_at_risk="2248"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" subjects_affected="247" subjects_at_risk="2240"/>
                <counts group_id="E2" subjects_affected="196" subjects_at_risk="2248"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>dizziness</sub_title>
                <counts group_id="E1" subjects_affected="189" subjects_at_risk="2240"/>
                <counts group_id="E2" subjects_affected="209" subjects_at_risk="2248"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>mood alteration or depression</sub_title>
                <counts group_id="E1" subjects_affected="236" subjects_at_risk="2240"/>
                <counts group_id="E2" subjects_affected="235" subjects_at_risk="2248"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>vaginal dryness</sub_title>
                <counts group_id="E1" subjects_affected="352" subjects_at_risk="2240"/>
                <counts group_id="E2" subjects_affected="343" subjects_at_risk="2248"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>cough</sub_title>
                <counts group_id="E1" subjects_affected="234" subjects_at_risk="2240"/>
                <counts group_id="E2" subjects_affected="266" subjects_at_risk="2248"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Paul Goss</name_or_title>
      <organization>Massachusetts General Hospital</organization>
      <phone>617-724-3118</phone>
      <email>pgoss@partners.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

